[Diversity and accessibility of smoking cessation aids in the internet]

AIM OF THE STUDY

Only a few smokers use smoking cessation aids. The Internet can act as a medium to improve the dissemination of traditional smoking cessation aids, but can also provide direct help by its own interactive capabilities. The purpose of this study is to give an overview of the different smoking cessation aids offered via the Internet and to categorise their contents.

METHODS

Two different search strategies were used to find smoking cessation aids on the Internet. The first was a search with the search engine Google. Six search terms were previously generated by interviews with one hundred smokers. Using these terms, the Google search resulted in a list of 106 websites. The second strategy was a direct search on 31 websites of different health-related institutions. To classify the smoking cessation aids on the websites, a system of different categories was developed.

RESULTS

The offers for smoking cessation on the Internet could be assigned to 11 categories. General information about smoking cessation was the most and interactive programs was the least represented category. The websites of the health-related institutions offered a larger variety of directly useable smoking cessation aids (39%) than the websites retrieved via Google (29%).

CONCLUSION

Interactive smoking cessation aids which provide individual support are still underrepresented on the Internet. Direct search strategies on the pages of health-related institutions were more promising than the use of a search engine. The proactive promotion of quality-controlled Internet offers seems to be important to capitalise on the potential of the Internet.

Postpartum Smoking Cessation and Relapse Prevention Intervention

The aim of the study was to test the effectiveness of a postpartum smoking cessation and relapse prevention intervention. Structural equation modeling techniques were applied to evaluate the impact of the intervention on smoking behavior and on non-behavioral variables derived from the Transtheoretical Model (TTM). Women were randomized to an intervention (I) and control group (C). Smoking status, TTM-variables, and control variables were assessed four weeks, six and 12 months postpartum. Membership in the intervention group significantly predicted non-smoking and higher self-efficacy six months, but not one year postpartum, after controlling for demographic, smoking, and postpartum risk variables.

Cellular and humoral immune response to a third generation hepatitis B vaccine

Liver transplantation is often the ultimate option of therapy for chronically hepatitis B virus (HBV) infected patients. Adoptive transfer of HBV immunity with the liver after vaccination of living liver donors (LLD) could be a new approach to prevent reinfection in the recipients. The time to achieve HBV immunity in LLD is usually short (1-2 months). Therefore, we established a short time immunization protocol (four injections in 2 weeks intervals) using Hepimmune, a recombinant vaccine that contains the L, M and S proteins of HBV. We examined cellular and humoral immune responses after immunization with Hepimmune and compared its immunogenicity to that of a standard HBV vaccine containing only the S protein (HBVAXPRO). Cellular immunity was measured by interferon (IFN)-gamma ELISpot and proliferation assay. HBV-specific T cells were detectable in the Hepimmune group after the second and in the standard group after the third vaccination. IFN-gamma production of T cells was significantly higher (P < 0.001) after the third vaccination with Hepimmune. Proliferative responses were also significantly (P < 0.01) higher in the Hepimmune group after the second to fourth vaccination. The humoral immune response could already be detected after the first immunization in nine of 15 Hepimmune vaccinated test persons while it was only observed in one of 15 probands of the later group. Titres differed significantly (P < 0.01) following all four vaccinations. Thus, Hepimmune appears to be a good candidate for short time immunization protocols.

Antibiotic administration early in life impairs specific humoral responses to an oral antigen and increases intestinal mast cell numbers and mediator concentrations

In this study, we assessed the effect of administering the antibiotic amoxicillin to rat pups on the immune response to orally fed ovalbumin (OVA). We first established that amoxicillin administration durably altered the gut microbiota of these animals. In parallel, we observed that the induction of the specific humoral response to ovalbumin was impaired when it occurred during antibiotic administration to the rat pups. We also examined the consequences of those observations on further allergic reactions. Amoxicillin administration had no significant impact on subsequent sensitization to OVA, as nonexacerbated systemic allergic responses were induced in antibiotic-treated animals. However, increased rat mast cell protease II levels and higher mast cell numbers were detected in their small intestines, independently of the antigen administration. Globally, our data suggest that antibiotic administration early in life negatively affects the specific immune response to a luminal antigen when it is first introduced during antibiotic administration. The increased mast cell numbers and mediator concentrations in the intestinal mucosae of the antibiotic-treated animals may testify to the early stages of an altered immune system homeostasis.

Smoking status, obesity and hypertension in a general population sample: a cross-sectional study

BACKGROUND

In some studies, hypertension is more common in never and former smokers than in current smokers.

AIM

To examine the associations between hypertension and smoking status, when divided into subgroups by overweight and obesity.

DESIGN

Cross-sectional study.

METHODS

We used data from a national health survey with a probability sample of the national population of Germany aged 18 to 79 (n = 6903 with complete data). Smoking status data were collected via questionnaire. Obesity and overweight were assessed by body mass index, hypertension by blood pressure measurement and by participants' statements about antihypertensive treatment. Analyses were adjusted for gender, age, history of coronary artery disease, serum cholesterol levels, alcohol drinking, exercise, and education.

RESULTS

Obese former smokers who were abstinent for 3 or more years had an adjusted odds ratio (OR) 3.6 (95% confidence interval, CI 2.3-5.7) for mild hypertension (> or =140 mmHg systolic or > or =90 mmHg diastolic blood pressure) and an adjusted OR 6.5 (95%CI 3.6-11.8) for moderate or severe hypertension (> or =160 mmHg systolic or > or =100 mmHg diastolic). Normal weight never or former smokers did not differ from normal weight current smokers smoking > or =15 cigarettes/day with regard to likelihood of hypertension (normal weight never smokers, OR 1.1, 95%CI 0.8-1.5; normal weight former smokers, abstinent 3 or more years, OR 0.8, 95%CI 0.5-1.3).

DISCUSSION

In this nationally representative sample, never or former smoking was unrelated to hypertension among normal weight individuals.

No considerable long-term weight gain after smoking cessation: evidence from a prospective study

The aim of the study was to analyse predictors of the body mass index (BMI) after smoking cessation. The sample included 4075 residents aged 18-64 years in a northern German area (participation rate 70.2%), drawn randomly from the resident registration files, among them 1545 current and 903 former daily smokers. The current smokers were followed up 36 months after baseline. Face-to-face in-home computer-aided interviews (Composite International Diagnostic Interview) including questions about body weight and height at baseline and postal questionnaires at follow-up were employed. The data reveal that the number of cigarettes smoked at time of peak consumption in life contributed substantially, and years of abstinence from daily smoking contributed marginally to the BMI in a general linear model. It is concluded that the contribution of smoking cessation to the BMI increase was practically negligible. Efforts to prevent weight gain after smoking cessation should focus especially on heavy smoking.

Förderung der Intention zur Tabakabstinenz bei Patienten in der hausärztlichen Praxis

BACKGROUND

General practitioners can reach large number of smokers. Their good interpersonal relationship with patients promises successful guidance with regard to smoking. However, little is known about the accessibility of smokers to intervention in general practice and about the motivation to abandon smoking. There is a lack of information concerning the GPs' perceived responsibility for smoking counselling. The goal of the study is to examine to what extent smokers can be advised in general practice and how GPs' assess the practicability of such counselling.

METHODS

The sample consisted of consecutive general practices patients. A random sample of 39 GPs was drawn and 34 took part in the study. Of 3434 patients, 99.7 % participated in the screening procedure. Inclusion criteria (age 18 to 70 years, admitted smokers), were met by 551 subjects. The participation rate was 81.4 % (n = 449). All GPs received a single training session. Counselling was tailored to the motivation to quit. More than 60 % of the patients were not motivated to stop smoking.

RESULTS

Following the study design, 87.8 % of all smoking patients were counselled by GPs. A total of 79.3 % among the GPs considered the intervention to be practicable.

CONCLUSIONS

Despite a low motivation to quit smoking in the general practice, 80 % of the smoking patients can be reached by interventions. Furthermore, since the agreement of the GPs concerning practicability was almost 80 %, measures should be initiated to promote counselling for all smokers within the scope of medical consultation.

[Platelet Adhesion Assay (PADA), a new quantitative test for assessment of platelet function and therapeutic drug monitoring of GPIIb/IIIa and ADP receptor antagonists]

Platelet ADhesion Assay (PADA) is a POCT capable method for quantitative determination of platelet adhesiveness. Using special polymer particles and test conditions adjusted to the physiologic conditions, the current functional state of blood platelets is determined directly from a whole blood sample. Within a short time, using little technical equipment and small sample volume, a therapeutic drug monitoring of GP IIb/IIIa and ADP receptor antagonists is possible, too. Whereas in healthy volunteers dose/effect curves of GP IIb/IIIa antagonists vary only slightly, in thrombopilic patients there are big variations. Differences in efficacy up to drug resistance may occur also in use of the ADP receptor antagonist clopidogrel. A therapeutic drug monitoring of GP IIb/IIIa- and ADP receptor antagonist therapy is essential and becomes feasible using PADA, also as long-term drug monitoring of ADP receptor antagonists and detection of drug resistance. Additionally, an individual ex vivo dose estimation for GP IIb/IIIa antagonists is possible. PADA allows diagnostics of pathological platelet function in thrombophilic patients as well as long-term therapeutic drug monitoring due to its simple handling.

A short form of the Fagerström Test for Nicotine Dependence and the Heaviness of Smoking Index in two adult population samples

Few data exist about the Fagerström Test for Nicotine Dependence (FTND) and the Heaviness of Smoking Index (HSI) from population samples. The goal was to prove to what degree (1) a reduced item solution of the FTND and (2) the HSI represent the FTND. Two randomized adult population samples were used from northern Germany. Sample 1 included 1462 and sample 2 included 1042 current daily cigarette smokers aged 20-64 years with FTND data. The results show that four items of the FTND as well as the HSI represent the FTND. It is concluded that both are valid measures of the urge to smoke and the tobacco-smoke-seeking behavior.

PADA, der neue Plättchenadhäsionstest

Der Platelet ADhesion Assay (PADA) ist eine POCT-fähige Methode zur quantitativen Bestimmung der Plättchenadhäsivität. Durch spezielle Polymerpartikel und Testbedingungen, die den physiologischen Verhältnissen im Organismus angepasst sind, wird aus einer Vollblutprobe direkt der aktuelle Funktionszustand der Blutplättchen bestimmt.

Innerhalb kurzer Zeit, mit geringem Geräteaufwand und minimalem Probenvolumen ist auch ein therapeutisches Monitoring von Glykoprotein(GP)-IIb/IIIa- und ADP-Rezeptor-Antagonisten möglich. Während bei Gesunden die Dosis/Wirkungskurven der GP-IIb/IIIa-Antagonisten nur gering variieren, schwanken sie bei thrombophilen Patienten stark. Wirkungsunterschiede bis zur Arzneimittelresistenz treten auch beim ADP-Rezeptor-Antagonisten Clopidogrel auf. Ein therapeutisches Monitoring der GP-IIb/IIIa- und ADP-Rezeptorantagonisten ist essenziell und mittels PADA realisierbar – auch als Langzeit-Monitoring für ADP-Rezeptorantagonisten sowie zur Detektion einer Arzneimittelresistenz. Mit dem PADA ist eine individuelle Ex-vivo-Dosisrelation für GP-IIb/IIIa-Antagonisten möglich. Der PADA erlaubt die Diagnostik einer pathologisch veränderten Plättchenfunktion thrombophiler Patienten und durch die einfache Handhabung auch die Therapieüberwachung über längere Zeit.